Markets

Why Adaptimmune Therapeutics Stock Is Sinking Today

What happened

Adaptimmune Therapeutics (NASDAQ: ADAP), a clinical-stage cancer specialist, is having another off day today. Specifically, the biotech's shares are down by 16.8% as of 10:55 a.m. EDT Friday morning. For the week, Adaptimmune's stock is now down by over 20%.

What's behind this sudden downturn? Earlier today, Adaptimmune announced the early release of an abstract for an upcoming presentation at the virtual Society for the Immunotherapy of Cancer conference on Nov. 11, 2020. While the abstract implies that the company's SPEAR (Specific Peptide Enhanced Affinity Receptor) T-cell therapy, ADPA2M4CD8, may sport anti-tumor activity in both head and neck cancer, as well as esophagogastric junction cancer, investors apparently wanted even more from this next-generation cell therapy.

Two cancer cells dividing.

Image source: Getty Images.

So what

Adaptimmune is attempting to pull off a rather difficult feat with its SPEAR T-cell pipeline. Namely, the biotech is trialing T-cell therapies as game-changing treatments for solid tumors. It's important to understand that T-cell therapies have yet to show much in the way of efficacy outside of the realm of liquid tumors.

Adaptimmune's novel oncology pipeline targeting solid tumors, in turn, clearly represents a high-risk, high-reward proposition for investors. Investors, for their part, are rightfully eager to have some form of clear-cut evidence that this unique approach will indeed pay off. Today's data release -- at least in the eyes of some -- seemingly didn't scratch that itch.

Now what

The somewhat odd part of this story is that the abstract in question only contained prelimary data for five patients. Investors arguably shouldn't be drawing any conclusions -- good or bad -- from such a limited data release. So, if you're the risk-tolerant type, it might be worth picking up a few shares of this beaten down biotech stock today.

10 stocks we like better than Adaptimmune Therapeutics
When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has tripled the market.*

David and Tom just revealed what they believe are the ten best stocks for investors to buy right now... and Adaptimmune Therapeutics wasn't one of them! That's right -- they think these 10 stocks are even better buys.

See the 10 stocks

*Stock Advisor returns as of September 24, 2020

George Budwell has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

In This Story

ADAP

Latest Markets Videos

    The Motley Fool

    Founded in 1993 in Alexandria, VA., by brothers David and Tom Gardner, The Motley Fool is a multimedia financial-services company dedicated to building the world's greatest investment community. Reaching millions of people each month through its website, books, newspaper column, radio show, television appearances, and subscription newsletter services, The Motley Fool champions shareholder values and advocates tirelessly for the individual investor. The company's name was taken from Shakespeare, whose wise fools both instructed and amused, and could speak the truth to the king -- without getting their heads lopped off.

    Learn More